FABP1 suppression has been correlated to the reduction of steatosis, inflammation and oxidative stress, suggesting that FABP1 downregulation may slow down the progression of NAFLD into NASH [70]. The gene discussed is FABP1; the disease is metabolic dysfunction-associated steatotic liver disease.